Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-20

Study Completion Date

2020-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with three lesions of alopecia areata are randomly recruited in this study. Each lesion is randomized in to receiving either carboxytherapy in one lesion, intralesional steroids in another lesion and combination of both in the third lesion.

Treatment period is 3 months followed by a follow-up period of 2 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata

NCT04964349

Alopecia Areata

UNKNOWN EARLY_PHASE1

Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata

NCT05485571

Alopecia Areata

UNKNOWN NA

Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study

NCT05502952

Alopecia Areata

UNKNOWN NA

Superficial Cryotherapy Versus Microneedling in Alopecia Areata

NCT04680234

Alopecia Areata

COMPLETED NA

Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids

NCT05017454

Alopecia Areata

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carboxytherapy

Group Type ACTIVE_COMPARATOR

Carboxytherapy

Intervention Type DEVICE

Carbon dioxide (CO2) gas in injection form

Intralesional steroids

Group Type ACTIVE_COMPARATOR

Intralesional Steroid Injection

Intervention Type DRUG

triamcinolone acetonide 8 mg/mL

Combination of carboxytherapy and intralesional steroids

Group Type ACTIVE_COMPARATOR

Carboxytherapy

Intervention Type DEVICE

Carbon dioxide (CO2) gas in injection form

Intralesional Steroid Injection

Intervention Type DRUG

triamcinolone acetonide 8 mg/mL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carboxytherapy

Carbon dioxide (CO2) gas in injection form

Intervention Type DEVICE

Intralesional Steroid Injection

triamcinolone acetonide 8 mg/mL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* early localized scalp alopecia areata
* patients who did not receive any medication for at least 2 months before starting the study Patients who agreed to join the study and signed written consent.

Exclusion Criteria

* pregnant, and lactating females and those with unrealistic expectation.
* Alopecia totalis or universalis or ophiasis or cicatrising alopecia
* Usage of systemic treatment of alopecia areata 2 months prior to the study.
* Any scalp lesion within the treated area
* Bleeding diathesis, severe anemia or platelet disorders
* Medical conditions such as autoimmune diseases.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No